



ISSN: 2230-9926

Available online at <http://www.journalijdr.com>

IJDR

International Journal of Development Research
Vol. 08, Issue, 05, pp.20568-20572, May, 2018



ORIGINAL RESEARCH ARTICLE

OPEN ACCESS

STUDY OF ANEMIA IN RHEUMATOID ARTHRITIS

*¹Dr. Manju Kumari, ²Dr Sadhna Marwah and ³Dr Vivek Arya

¹Senior Resident, PGIMER, Dr. R.M.L Hospital New Delhi India

²Professor, PGIMER, Dr. R.M.L Hospital New Delhi

ARTICLE INFO

Article History:

Received 08th February, 2018
Received in revised form
27th March, 2018
Accepted 17th April, 2018
Published online 31st May, 2018

Key Words:

DAS-28 score, Iron profile,
Modified health
Assessment questionnaires,
Serum ferritin.

ABSTRACT

Introduction & Background: Rheumatoid arthritis (RA) is a chronic inflammatory systemic disease of unknown etiology with a variety of extraarticular manifestations including fatigue, subcutaneous nodules, lung involvement, pericarditis, peripheral neuropathy, vasculitis, and hematologic abnormalities including anaemia. Anemia in rheumatoid arthritis is common and multifactorial. We studied the prevalence, type of anemia and its correlation with disease activity in Indian patients in a tertiary care hospital.

Aims: To diagnose the type of anemia in patients with rheumatoid arthritis and to correlate it with disease activity of rheumatoid arthritis and medication.

Settings and design: It is a cross sectional analytical study carried out at department of pathology and department of medicine.

Patient/ Material and Methods: Fifty patients (45 female and 5 males) with recent onset (<5 years) RA were included in the study. The anemic patients were evaluated for the type of anemia. A serum ferritin level of $\leq 50 \mu\text{g/l}$ was taken as cut off for defining iron deficiency anemia. Disease activity assessment was done using DAS-28 score and functional disability assessment by using modified health assessment questionnaires (MHAQ) in all the patients.

Statistical Analysis: Data was analysed using SPSS (version 20). P value < 0.05 was considered significant.

Results: Forty two patients (84%) out of fifty were found to be anemic with 19 patients (45.2%) having iron deficiency anemia and 23 (54.8%) having anemia of chronic disease. None of the patients had megaloblastic anemia. In anemic group DAS-28 score and MHAQ were found to be 4.95 ± 1.21 and 1.07 ± 0.58 respectively and in non-anemic group 3.41 ± 0.60 and 0.40 ± 0.36 respectively. The disease activity was higher in patients with iron deficiency anemia than those with anemia of chronic disease, but was not statistically significant.

Conclusions: Anemia is a common extraarticular manifestation in patients with RA and significantly correlates with higher disease activity. Anemia of chronic disease is the most common type of anemia in these patients. However, further studies including a larger number of patients with long term follow up are needed for conclusive results.

Copyright © 2018, Dr. Manju Kumari. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citation: Dr. Manju Kumari, 2018. "Study of anemia in rheumatoid arthritis", *International Journal of Development Research*, 8, (05), 20568-20572.

INTRODUCTION

Rheumatoid arthritis (RA) is a chronic inflammatory disease of unknown etiology marked by a symmetric, peripheral polyarthritis. It is the most common form of chronic inflammatory arthritis and often results in joint damage and physical disability. RA is a systemic disease which may result in a variety of extra-articular manifestations, including fatigue, subcutaneous nodules, lung involvement, pericarditis, peripheral neuropathy, vasculitis, and hematologic abnormalities including anemia (Longo, 2012).

*Corresponding author: Dr. Manju Kumari
Senior Resident, PGIMER, Dr. R.M.L Hospital New Delhi India

As the disease progresses, patients with RA suffer significant disability and a marked reduction in their quality of life (Smolen, 2003). The disease activity is assessed with the help of DAS-28 score. The World Health Organization estimates that RA affects 23.7 million people worldwide with a prevalence of 0.5–1.0% of the adult population (Seldin, 1999). Anemia is the most common blood disorder affecting nearly one-fourth of the population of the world and two-third of patients with RA. The estimated lifetime prevalence of anemia in general population is 13.7%. The prevalence of anemia in the adult population in India is 47.5% (anemia defined as per WHO) with higher prevalence in females (50%) than in males (44.3%) (Nutritional anaemias, 1968 and Malhotra, 2004). The

commonest cause of anemia worldwide is iron deficiency. The different types of anemia which can occur in rheumatoid arthritis can be anemia of chronic disease (ACD), iron deficiency anemia (IDA) (Nutritional anaemias, 1968), aplastic anemia and anemia due to treatment with NSAIDs and DMARDs. The commonest form of anemia is ACD. It is not a very severe form of anemia but is refractory to most forms of treatment. The severity of anemia parallels the degree of inflammation, correlating with the levels of erythrocyte sedimentation rate (ESR) and serum C-reactive protein (CRP). Also the platelet counts may be elevated in RA as an acute-phase reactant (Longo, 2012).

MATERIALS & METHODS

Fifty patients (45 female and 5 males) with recent onset (<5 years) RA diagnosed as per 2010 American College of Rheumatology/European League against Rheumatism Classification Criteria with age more than 18 years were included in the study (13). Patients with known comorbid conditions like tuberculosis, diabetes mellitus, pregnancy, arthropathies other than RA, patients on hematinics or with chronic bleeding (piles, menorrhagia, oesophageal varices) were excluded from the study. Complete blood counts, serum iron profile, serum ferritin, serum vitamin B12 and folate

Table/ Figure 1. Comparison of various parameters in anemic and non anemic RA patients

Parameter	Group	Number of patients	Mean	Standard deviation	p- value
TJC	Anemic	42	5.43	4.27	0.025
	Non anemic	8	1.88	1.13	
SJC	Anemic	42	3.81	4.46	0.043
	Non anemic	8	0.5	0.54	
ESR	Anemic	42	39.76	21.998	0.146
	Non anemic	8	27.25	21.48	
HAQ Score	Anemic	42	1.07	0.58	0.003
	Non anemic	8	0.4	0.36	
DAS-28 Score	Anemic	42	4.95	1.21	0.001
	Non anemic	8	3.41	0.6	
VAS	Anemic	42	55	19.57	<0.0001
	Non anemic	8	22.5	11.65	

Table/ Figure 2. Comparison of various parameters between patients with IDA and patients with ACD.

Parameter	Group	Number of patients	Mean	Standard deviation	p- value
TJC	ACD	23	4.26	2.47	0.05
	IDA	19	6.84	5.5	
SJC	ACD	23	2.65	2.52	0.064
	IDA	19	5.21	5.82	
ESR	ACD	23	31.52	22.06	0.006
	IDA	19	49.74	17.76	
HAQ Score	ACD	23	0.84	0.45	0.003
	IDA	19	1.35	0.6	
DAS-28 Score	ACD	23	4.5	1.01	0.007
	IDA	19	5.49	1.23	
VAS	ACD	23	48.26	17.23	0.012
	IDA	19	63.16	19.52	
Serum ferritin	ACD	23	90.57	22.78	<0.0001
	IDA	19	32.05	10.4	

According to various studies 30-60 % of RA patients residing in developed countries have of IDA (Majithia, 2007; Efthimiou, 2010; Macfarlane, 2011 and Vreugdenhil, 1990). The anemia of chronic disease, IDA and others can be differentiated with the help of RBC indices, serum ferritin, serum transferrin receptors and marrow staining for iron. Bone marrow staining is the definitive diagnostic method to differentiate ACD and IDA but is an invasive process. RBC indices show an overlap between ACD and IDA, so we need a noninvasive method to differentiate them. IDA is associated with serum ferritin less than 20µg/dl; a level greater than 100 µg/dl excludes IDA. As serum ferritin is an acute phase reactant protein it can be raised in inflammatory conditions creating an error in diagnosis. The presence of low serum ferritin (< 50 µg/l) along with high serum transferrin levels (50 g/l) and decreased mean corpuscular volume (MCV) of erythrocytes (80 fl) results in 100% sensitivity and specificity for the detection of iron deficiency and if serum ferritin is >50 µg/l and IDA is excluded then it is considered as ACD (10-12).

levels were performed. Anemia was defined as hemoglobin <12 g/dl in females and <13 g/dl in males. The anemic patients were evaluated for the type of anemia and serum ferritin ≤50 µg/l was taken as cut off for defining iron deficiency anemia. Disease activity assessment was done using DAS-28 score and functional disability assessment by using modified health assessment questionnaires (MHAQ) in all the patients (Steenland, 2001 and Kumar, 2002).

RESULTS

Forty two patients (84%) out of fifty were found to be anemic with 19 patients (45.2%) having iron deficiency anemia and 23 (54.8%) having anemia of chronic disease. None of the patients had megaloblastic anemia. Comparisons of various parameters were done between anemic and nonanemic groups, which showed significantly higher prevalence of tender, swollen joint counts and erythrocyte sedimentation rate.

Table/ Figure 3. Comparison of various studies with present study

Authors	Disease variable	Anemic group	Nonanemic group	P value
Tazi, <i>et al</i>	HAQ score	1.44 ± 0.81	0.95 ± 0.77	<0.001
	DAS 28 score	5.45 ± 1.55	4.7 ± 1.69	<0.001
	TJC	5.37±6.32	2.23±4.27	<0.001
Agarwal <i>et al</i>	SJC	8.81±8.08	3.82±5.77	<0.001
	DAS 28 score	5.19±1.50	3.82±1.36	<0.001
	TJC	17.4±5.45	8.27±5.87	0.0002
Borah <i>et al</i>	SJC	9.75±3.78	4.09±2.66	0.0001
	HAQ score	6.85±0.64	4.76±1.29	0.0001
Ganna <i>et al</i>	DAS 28 score	1.41±0.44	0.7±0.25	0.001
	TJC	31.42 ± 10.07	18.52 ± 11.28	0.001
	SJC	28.67 ± 9.01	16.53 ± 8.27	0.002
	HAQ score	1.98 ± 0.551	.4 ± 0.6	0.02
	DAS 28 score	5.2 ± 1.3	2.8 ± 1.1	0.001
	TJC	5.43±4.27	1.88±1.13	0.025
Present study	SJC	3.81±4.46	0.50±0.54	0.043
	HAQ score	1.07±0.58	0.40±0.36	0.003
	DAS 28 score	4.95±1.21	3.41±0.60	0.001

In anemic group DAS-28 score and MHAQ were found to be 4.95±1.21 & 1.07±0.58 respectively and in non-anemic group 3.41±0.60 & 0.40±0.36 respectively which was highly significant (Table/Figure.1). All these parameters were further compared between the patients having IDA and ACD. The HAQ score and VAS was significantly higher in patients with IDA than in patients with ACD. (HAQ and VAS p-value 0.003 and <0.012 respectively). Also there was a significant difference in serum ferritin levels in between the patients with IDA and those with ACD (p= <0.001) (Table/Figure. 2).




Table /Figure 4. Correlation between anemia and HAQ




Table /Figure 5. Correlation between anemia and DAS-28 score




Table /Figure 6. Serum ferritin in anemic and non anemic patient

DISCUSSION

In this study prevalence and type of anemia in patients with rheumatoid arthritis and it's correlation with disease activity were assessed. The mean age of the study population was 42.48 ±12.07 years and the median value was 42 years. This is similar to a study by Agarwal *et al* (Agrawal, 2006) where the mean age was 43.9±11.83 years. Median duration of disease was 3 years. On clinical examination, tender joint counts ranged from 0 to 24, with a median of 4. Swollen joint counts ranged from 0 to 20, with a median of 2. All patients in this study had active disease. Functional disability in rheumatoid arthritis (RA) reflects the cumulative effects of the disease over time. Various factors are responsible for functional disability, such as pain, swollen joints, tender joints and joint deformities. In this study, functional disability was assessed by HAQ score using the Indian version of the health assessment questionnaire. HAQ score is an important indicator of disability in RA. It ranged from 0 to 2.4, with a mean of 0.961±0.6 (median=1.0). This result is similar to the study conducted by Aletaha *et al*. (D2) in which 1342 patients with early RA were assessed for response to treatment after one year and the baseline mean HAQ score. Among 50 patients, mild, moderate and severe functional disability (HAQ: 0-<1, 1-<2, 2-3) was present in 24, 22 and 4 patients, respectively (Table/Figure.4). Disease activity was quantified using DAS28 scores. Scores ranged from 2.8 to 8.14, with a mean of

4.70±1.27. Out of 50 patients, 9 patients (18%) were in the low disease activity category (DAS28: 2.6-<3.2), 21 patients (42%) were in the moderate disease activity category (DAS28: 3.2 – 5.1) and 20 patients (40%) were in severe disease activity category (DAS: >5.1). None of the patients were in remission phase (DAS28: <2.6) (Fig. 2) Most of the patients had high disease activity reflecting the fact that this study included newly diagnosed patients with RA and few of them (3 patients) were not taking treatment in the recent past. In a study by Tazi *et al* (Tazi, 2015) in 1129 patients of rheumatoid arthritis, the mean DAS 28 score was 4.94 ± 1.68, which is similar to the value of the present study. In this study, anaemia was defined as a haemoglobin level < 13 g/dl in men and < 12 g/dl in women. 42 patients (84%) were found to be anemic. This was higher than the figures reported in other studies (33%-71%) (Agrawal, 2006 and Wolfe, 2006) as WHO criteria were used for defining anemia in our present study whereas Hb< 11 g/dl in women and <12g/dl in men was used in most of the other studies. ESR was elevated in 47 patients (94%) with a mean of 39.76±22 mm in 1 st hour in anemic patients and 27.25±21.48 in nonanemic patients.

There was no significant difference between the two groups. Serum ferritin was done in all patients. A value of ≤50 µg/dl of serum ferritin was present in 19 patients with mean of 32.05±10.40 µg/dl, all of these had low serum iron levels (mean±S.D=29.45±9.41), increased total iron binding capacity (mean±S.D=443±37.42), unbound iron binding capacity (mean±S.D= 413.63±41.15) and decreased transferrin saturation (mean±S.D= 11.16±4.33). Thirty one patients had serum ferritin levels more than 50µg/dl. Among these 23 patients were anemic and 8 were nonanemic (Table/Figure. 6). Anemic patients with serum ferritin >50 were categorized as having anemia of chronic disease (n=23). These patients had low to normal serum iron levels (mean ±S.D=64.17±16.95), TIBC (mean±S.D=273.57±54.10 µg/dl) and UIBC (mean±S.D=204.87±51.13µg/dl) towards lower level of normal limits and normal to increased transferrin saturation (mean±S.D=28.18 ±4.70 %). Iron profile of non anemic patients was within normal limits. Thus, on the basis of serum ferritin and iron profile the anemic patients were divided into those with ACD and those with IDA. Twenty three patients (54.8%) had ACD and 19 patients (45.2%) had IDA. ACD was the commonest type of anemia in patients with RA. However, the prevalence of IDA was higher than that reported in other studies as WHO criteria were used in the present study. Our results are comparable to a study by Agarwal *et al.* in which 51.6% patients had ACD and 48.8% had IDA (Agrawal, 2006).

A higher degree of functional disability and disease activity, measured by HAQ and DAS 28 score were noted in anemic patients (1.06 versus 0.40, p=0.003 and 4.95 versus 3.41, p=0.001 respectively). Anemic patients also had significantly higher number of tender joints (p=0.025) and swollen joints (p=0.043) which reflects that severity of anemia is related with disease activity and inflammation. (Table/figure. 4 and 5) This was similar to the results of previous studies. (Table/figure. 3) In anemic patients there were significantly higher HAQ and DAS 28 scores in patients with IDA than in those with ACD. Serum ferritin is a reliable marker of iron stores in iron deficiency anemia. But as it is an acute phase reactant it does not correlate well with iron stores in patients with RA. In the present study, serum ferritin level of ≤50 µg/l was used to

categorise patients having IDA. As RA is an inflammatory disease a higher cut off value for serum ferritin is required to define IDA in patients with than those having uncomplicated IDA. Various studies have reported the cut of values of serum ferritin in between 30 and 70 µg/l to define iron deficiency anemia in patients with RA (Bultink, 2001). Serum transferrin receptor (sTfR) levels and its ratio to serum ferritin (sTfR-ferritin index <1) has been shown to be of value in distinguishing IDA from ACD (Bultink, 2001). However a single sTfR value is of limited value in determining the level of iron storage in an individual with RA. Also this test is expensive and not widely available in a developing country like India. At present no single test is available to distinguish ACD from IDA in patients with RA. Thus, anemia screening should be a part of routine management of rheumatoid arthritis in order to reduce disease associated morbidity and to establish appropriate treatment for these patients.

Conclusion

It is concluded that anemia is a common extra-articular manifestation in patients with rheumatoid arthritis with a prevalence of 84% and it was significantly correlated with higher disease activity. Anemia of chronic disease is the most common type of anemia in patients with rheumatoid arthritis. It is difficult to differentiate iron deficiency anemia and anemia of chronic disease on the basis of serum ferritin alone in patients with RA, as it is an acute phase reactant it can be raised in some of the patients even in the presence of iron deficient state. Some of the patients can also have concomitant ACD and IDA. It is also concluded that better hemoglobin levels are associated with lesser disability and better quality of life. Hence screening and treating for anemia is important in management of patients with rheumatoid arthritis. However, further studies including a larger number of patients with long term follow up are needed for conclusive results.

REFERENCES

- Agrawal, S., Misra, R., Aggarwal, A. 2006. Anemia in rheumatoid arthritis: high prevalence of iron-deficiency anemia in Indian patients. *Rheumatology International* 26(12):1091-95.
- Bultink, I.E., Lems, W.F., van de Stadt, R.J., Dinant, H.J., Leyte, A., Park, D.S., de Koning, M.H., Dijkmans, B.A. 2001. Ferritin and serum transferrin receptor predict iron deficiency in anemic patients with rheumatoid arthritis. *Arthritis Rheum* 44:979-981
- Efthimiou, P., Kukar, M. 2010. Complementary and alternative medicine use in rheumatoid arthritis: proposed mechanism of action and efficacy of commonly used modalities. *Rheumatology international.*, 30 (5): 571-586.
- Kitas, G.D., Erb, N. 2003. Tackling ischaemic heart disease in rheumatoid arthritis. *Rheumatology (Oxford, England).*, 42(5):607-613
- Kumar, A., Malaviya, A.N., Pandhi, A., Singh, R. 2002. Validation of an Indian version of the Health Assessment Questionnaire in patients with rheumatoid arthritis. *Rheumatology (Oxford, England).* 41(12):1457-59.
- Longo, D.L., Kasper, D.L., Jameson, J.L., Fauci, A.S., Hauser, S.L., Loscalzo, J. 2012. Immune mediated, inflammatory, and rheumatologic disorders. Dennis L.Kasper, *et al.* Harrison's principles of internal medicine. 19th edition. New York, Mc Graw hill education. 18: 2738-51.

- Macfarlane, G.J. *et al.* 2011. Evidence for the efficacy of complementary and alternative medicines in the management of rheumatoid arthritis: a systematic review. *Rheumatology (Oxford)*, 50(9): 1672-1683.
- Majithia, V., Geraci, S.A. 2007. Rheumatoid arthritis: diagnosis and management. *American journal of medicine*. 120(11):936-939.
- Malhotra, P. 2004. Prevalence of anemia in adult rural population of north India. *The journal of association of physicians of India*. 52:18-20.
- Nutritional anaemias. 1968. Report of A WHO Scientific Group. World Health Organ Technical Report Series., 405: 5-37
- Porter, D.R., Sturrock, R.D., Capell, H.A. 1994. The use of serum ferritin estimation in the investigation of anemia in patients with rheumatoid arthritis. *Clinical and experimental rheumatology*., 12(2):179-182.
- Seldin, M., Amos, C., Ward, R., Gregersen, P. 1999. The genetics revolution and the assault on rheumatoid arthritis. *Arthritis & Rheumatism*. 42(6):1071-1079.
- Smolen, J., Steiner, G. 2003. Therapeutic strategies for rheumatoid arthritis. *Nature Reviews Drug Discovery*. 2(6):473-488.
- Steenland, K., Sanderson, W., Calvert, G.M. 2001. Kidney disease and arthritis in a cohort study of workers exposed to silica. *Epidemiology*., 12:405-412.
- Tazi, *et al.* 2015. Prevalence of Anemia and its Association with Parameters of Rheumatoid Arthritis Patients: A Study from the Moroccan Quest - *RA Data J Palliat Care Med* 5:221
- The 2010 ACR-EULAR classification criteria for rheumatoid arthritis. Available from http://www.rheumatology.org/practice/clinical/classification/ra/ra_2010.asp. Accessed on 4/3/2016.
- Vreugdenhil, G., Baltus, C.A., van Eijk, H.G., Swaak, A.J.G. 1990. Anemia of chronic disease: diagnostic significance of erythrocyte and serological parameters in iron deficient rheumatoid arthritis patients. *British journal of rheumatology*. 29:105-110.
- Vreugdenhil, G., Swaak, A.J. 1990. Anaemia in rheumatoid arthritis: pathogenesis, diagnosis and treatment. *Rheumatol international*., 9(6):243-257.
- Wolfe, F., Michaud, K. 2006. Anemia and renal function in patients with Rheumatoid Arthritis. *The journal of rheumatology*. 33:1516-1522.
